Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7441 to 7455 of 7675 results

  1. Venglustat for treating gangliosidoses in people 2 years and over ID 6358

    In development [GID-TA11601] Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Atezolizumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6148]

    In development [GID-TA11074] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Nivolumab with ipilimumab for untreated advanced renal cell carcinoma (TA581)

    This guidance has been updated and replaced by NICE technology appraisal guidance 780.

    Technology appraisal guidance
    Published
    15 May 2019

  4. Bimatoprost implant for treating open angle glaucoma or ocular hypertension when topical treatments are unsuitable [ID6180]

    In development [GID-TA11146] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Atezolizumab for adjuvant treatment of high-risk locally advanced squamous cell head and neck cancer [ID4052]

    In development [GID-TA10933] Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Sacituzumab govitecan for treating unresectable metastatic urothelial cancer [ID6150]

    In development [GID-TA11009] Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy (TA579)

    This guidance has been replaced by NICE's technology appraisal guidance on abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy.

    Technology appraisal guidance
    Published
    8 May 2019

  8. Soticlestat for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over TSID 10632

    In development [GID-TA11631] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Dexmedetomidine for treating agitation associated with schizophrenia TS ID 10726

    In development [GID-TA11015] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Dexmedetomidine for treating agitation associated with bipolar disorder in people 18 to 75 years [TS ID 10725]

    In development [GID-TA11014] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Voxelotor for treating haemolytic anaemia caused by sickle cell disease (TA981)

    NICE has withdrawn this guidance. Pfizer has informed the Medicines and Healthcare products Regulatory Agency (MHRA) that the product is being withdrawn. The recall notification is being shared with all healthcare professionals. No new people will start taking voxelotor in the UK. Healthcare professionals should discuss alternative treatment options with people currently having voxelotor.

    Technology appraisal guidance
    Published
    12 June 2024

  12. Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 4 or more therapies [ID2701]

    In development [GID-TA10568] Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Canakinumab for adjuvant treatment of resectable or resected stage 2A to 3B non-small-cell lung cancer [ID5114]

    Discontinued [GID-TA11026]

    Technology appraisal guidance
    Discontinued

  14. Durvalumab for untreated unresectable hepatocellular carcinoma [ID4068]

    Discontinued [GID-TA11041]

    Technology appraisal guidance
    Discontinued

  15. Atezolizumab for adjuvant treatment of renal cell carcinoma with a high risk of metastasis [ID5101]

    Discontinued [GID-TA11000]

    Technology appraisal guidance
    Discontinued